Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial

The American Journal of Gastroenterology
Paul J PockrosPEGASYS International Study Group

Abstract

This study compared the efficacy and safety of peginterferon alpha-2a 135 microg/wk, peginterferon alpha-2a 180 microg/wk and interferon alpha-2a in patients with chronic hepatitis C. A total of 639 patients received peginterferon alpha-2a 135 microg or 180 microg once weekly, or interferon alpha-2a 3 MIU thrice weekly for 48 wk. Sustained virological responses were significantly higher with peginterferon alpha-2a than with interferon alpha-2a 3 MIU (28% in the 135 microg and 180 microg peginterferon alpha-2a groups vs 11% with interferon alpha-2a, p = 0.001). The proportion of patients with clinically significant histological improvement was lower in the peginterferon alpha-2a 135 microg (48%) than the 180 microg group (58%, p = 0.035 vs peginterferon alpha-2a 135 microg), but similar to that in the interferon alpha-2a group (45%, p = 0.820 vs peginterferon alpha-2a 135 microg and p = 0.017 vs peginterferon alpha-2a 180 microg, respectively). The overall safety profiles were similar for the three treatments. In patients with chronic hepatitis C, peginterferon alpha-2a 135 microg/wk and 180 microg/wk produced similar sustained virological response rates, both of which were significantly higher than that achieved with interferon...Continue Reading

References

Sep 1, 1981·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R G KnodellJ Wollman
Dec 7, 2000·The New England Journal of Medicine·S ZeuzemM J Brunda
Dec 7, 2000·The New England Journal of Medicine·E J HeathcoteJ De Pamphilis
Feb 15, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K R ReddyJ DePamphilis
Aug 2, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K L LindsayUNKNOWN Hepatitis Interventional Therapy Group
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu

❮ Previous
Next ❯

Citations

Oct 30, 2009·The New England Journal of Medicine·Ching-Sheng Hsu, Jia-Horng Kao
Dec 29, 2010·Hepatitis Research and Treatment·Tatehiro Kagawa, Emmet B Keeffe
Jan 12, 2012·PloS One·Luis F López-CortésUNKNOWN Grupo para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas
Nov 22, 2005·Expert Opinion on Drug Delivery·Michael J GraceRonald W Bordens
Mar 27, 2007·Journal of Viral Hepatitis·A Mangia
Feb 22, 2007·Liver International : Official Journal of the International Association for the Study of the Liver·Eduardo Vilar GomezCaridad Ruenes Domech
Feb 10, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Calogero CammàAntonio Craxì
May 27, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Michael R CharltonStephen A Harrison
Jan 12, 2007·The Neurologist·Kenneth C Gorson
Feb 9, 2006·Current Treatment Options in Neurology·Kenneth C Gorson
Aug 19, 2007·European Journal of Gastroenterology & Hepatology·Junichiro NakamuraKouhei Akazawa
Dec 1, 2007·Nature Reviews. Drug Discovery·Michael P MannsMichael Houghton
Dec 23, 2017·Expert Opinion on Drug Metabolism & Toxicology·Ashly Maughan, Onyema Ogbuagu
Mar 6, 2009·Journal of Neurology·Roberto CavalloSimone Baldovino
Apr 17, 2010·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Izumi NamikiMasatoshi Kudo
Jul 27, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Paul J PockrosAnna S Lok
Jun 29, 2013·Nature Reviews. Drug Discovery·Michael P Manns, Thomas von Hahn
Oct 1, 2007·Expert Review of Gastroenterology & Hepatology·Paul J Pockros
Oct 7, 2009·Expert Review of Anti-infective Therapy·Alessio AghemoMassimo Colombo
Nov 7, 2009·Expert Opinion on Pharmacotherapy·Hidenori Toyoda, Takashi Kumada
Dec 29, 2011·CNS Drugs·Bernd C Kieseier, Peter A Calabresi
Feb 27, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Tahany AwadChristian Gluud
May 14, 2010·Clinical Pharmacology and Therapeutics·E SnoeckN Frey
Feb 22, 2011·Statistics in Medicine·Jeremie GuedjFrance Mentré
Dec 17, 2009·Scandinavian Journal of Infectious Diseases·Martin LaggingUNKNOWN Swedish Consensus Group
Nov 4, 2004·Alimentary Pharmacology & Therapeutics·R J Aspinall, P J Pockros
Mar 23, 2011·Current Hepatitis Reports·Hubert SungSammy Saab
Jan 13, 2006·Gastroenterology·Jules L Dienstag, John G McHutchison

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.